Sino Biopharmaceutical (HKG: 1177) announced that Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), its subsidiary, has recently completed full patient enrollment in the Phase III registration clinical trial of TQC2731 — its self‑developed Category 1 innovative drug, a humanized monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) — for the maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).
Clinical Development Milestone
| Item | Detail |
|---|---|
| Company | Sino Biopharmaceutical (HKG: 1177), via subsidiary Jiangsu Chia Tai Tianqing (CTTQ) |
| Product | TQC2731 – self‑developed Category 1 innovative drug |
| Molecule Class | Humanized anti‑TSLP monoclonal antibody |
| Study Phase | Phase III registration clinical trial |
| Indication | Maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) |
| Milestone | Full patient enrollment recently completed |
| Next Steps | Trial conduct toward primary analysis and NDA submission; timeline not disclosed |
Drug Profile & Mechanism of Action
- Molecule: TQC2731, a humanized monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) — an epithelial‑derived alarmin cytokine positioned at the initiation of the inflammatory cascade.
- Target Biology: Upon binding to the TSLP receptor on the cell surface, TSLP promotes activation of Type 2 inflammatory cells and the expression of multiple inflammatory cytokines, including IL‑4, IL‑5 and IL‑13 — the canonical drivers of type 2 airway inflammation.
- Non‑Type 2 Coverage: TSLP additionally enhances Th17 responses by influencing neutrophil function, participating in non‑Type 2 inflammatory reactions — a pathway implicated in CRSwNP phenotypes that respond poorly to type 2‑targeted biologics.
- Upstream Blockade: By antagonizing TSLP, TQC2731 is designed to inhibit inflammatory initiation signals upstream in the inflammatory cascade and reduce downstream cytokine release, exerting broad anti‑inflammatory effects.
- Differentiated Potential: TQC2731 is expected to simultaneously regulate both Type 2 and non‑Type 2 inflammation, offering broader inflammatory phenotype coverage — a differentiated development proposition in a disease with heterogeneous endotypes.
- Regulatory Category: Developed as a Category 1 innovative drug under China’s classification, independently discovered and advanced by CTTQ.
Disease Context – CRSwNP
- Chronic, Relapsing Burden: CRSwNP is a chronic inflammatory disease of the sinonasal mucosa characterized by recurrent polyp growth, nasal obstruction, and loss of smell, with high relapse rates after surgery and corticosteroid courses.
- Maintenance Need: The maintenance treatment setting addresses the core unmet need — durable control after initial therapy — where biologics have become the standard for severe disease.
- Phenotypic Heterogeneity: CRSwNP spans type 2 and mixed/non‑type 2 inflammatory endotypes; an upstream alarmin blocker like TQC2731 is positioned to treat across this heterogeneity, unlike single‑cytokine (IL‑4/IL‑13, IL‑5) targeted agents.
- Alarmin Class Momentum: TSLP sits at the apex of epithelial inflammatory signaling, and anti‑TSLP blockade has been clinically validated as a mechanism class in airway disease — supporting the translational rationale for TQC2731 in CRSwNP.
Market Impact & Outlook
- Registrational Progress: Completion of full Phase III enrollment moves TQC2731 decisively toward a potential registration filing with the NMPA, marking a key inflection point for the asset’s path to market.
- ENTYVIO‑Class Competition: The CRSwNP biologic space already includes established type 2‑targeted antibodies; TQC2731’s dual Type 2 / non‑Type 2 coverage through upstream TSLP blockade offers a differentiated positioning angle in both clinical and commercial terms.
- Pipeline Strategy: For Sino Biopharmaceutical and CTTQ, one of China’s largest generic‑to‑innovation pharmaceutical groups, a Category 1 biologic completing Phase III enrollment reinforces the group’s transition toward innovative immunology and respiratory franchises.
- Disclosures: Trial design details, sample size, endpoints, readout timing, and commercial forecasts were not disclosed in the announcement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development, trial readout, regulatory submission, and commercialization expectations for TQC2731 in CRSwNP. Actual results may differ materially due to risks including Phase III efficacy and safety outcomes, NMPA review timelines and requirements, competitive dynamics in the biologics market for nasal polyps, and market adoption. Completion of enrollment does not guarantee positive results or eventual approval.-Fineline Info & Tech
